Chronic Lymphocytic Leukemia — Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Citation(s)
A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions